Delayed
Nasdaq
01:00:00 2024-07-03 pm EDT
|
5-day change
|
1st Jan Change
|
44.91
USD
|
-0.36%
|
|
-1.86%
|
+26.12%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
777.7
|
1,403
|
1,840
|
1,244
|
1,699
|
2,190
|
-
|
-
|
Enterprise Value (EV)
1 |
777.7
|
1,403
|
1,840
|
1,244
|
1,699
|
2,190
|
2,190
|
2,190
|
P/E ratio
|
-79.1
x
|
515
x
|
-246
x
|
-75.3
x
|
-509
x
|
376
x
|
91.4
x
|
47.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
6.6
x
|
11.3
x
|
11.8
x
|
7.57
x
|
8.6
x
|
9.12
x
|
7.31
x
|
5.78
x
|
EV / Revenue
|
6.6
x
|
11.3
x
|
11.8
x
|
7.57
x
|
8.6
x
|
9.12
x
|
7.31
x
|
5.78
x
|
EV / EBITDA
|
-81.8
x
|
75.5
x
|
62.4
x
|
51.4
x
|
50.2
x
|
44.2
x
|
28.8
x
|
21.1
x
|
EV / FCF
|
-79,363,660
x
|
93,860,642
x
|
-
|
123,263,648
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
0%
|
-
|
0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
44,695
|
45,429
|
46,815
|
47,223
|
47,725
|
48,602
|
-
|
-
|
Reference price
2 |
17.40
|
30.88
|
39.30
|
26.34
|
35.61
|
45.07
|
45.07
|
45.07
|
Announcement Date
|
2/25/20
|
2/24/21
|
2/24/22
|
2/23/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
117.8
|
124.2
|
156.2
|
164.4
|
197.5
|
240.3
|
299.6
|
378.7
|
EBITDA
1 |
-9.507
|
18.58
|
29.48
|
24.2
|
33.88
|
49.57
|
76.12
|
103.8
|
EBIT
1 |
-11.25
|
2.372
|
-7.854
|
-17.06
|
-6.464
|
3.428
|
25.68
|
52.92
|
Operating Margin
|
-9.55%
|
1.91%
|
-5.03%
|
-10.38%
|
-3.27%
|
1.43%
|
8.57%
|
13.97%
|
Earnings before Tax (EBT)
1 |
-9.665
|
3.044
|
-7.582
|
-15.99
|
-2.368
|
7.379
|
27.81
|
53.84
|
Net income
1 |
-9.665
|
2.864
|
-7.471
|
-16.71
|
-3.182
|
5.482
|
25.61
|
49.51
|
Net margin
|
-8.2%
|
2.31%
|
-4.78%
|
-10.17%
|
-1.61%
|
2.28%
|
8.55%
|
13.07%
|
EPS
2 |
-0.2200
|
0.0600
|
-0.1600
|
-0.3500
|
-0.0700
|
0.1200
|
0.4929
|
0.9420
|
Free Cash Flow
|
-9.799
|
14.95
|
-
|
10.09
|
-
|
-
|
-
|
-
|
FCF margin
|
-8.31%
|
12.04%
|
-
|
6.14%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
80.42%
|
-
|
41.7%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
521.86%
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/20
|
2/24/21
|
2/24/22
|
2/23/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
47.59
|
36.07
|
37.05
|
38.55
|
52.69
|
41.02
|
45.92
|
45.58
|
65
|
51.28
|
52.58
|
56.07
|
80.35
|
63.41
|
66.65
|
EBITDA
1 |
12.77
|
3.243
|
2.772
|
3.325
|
14.86
|
1.7
|
4.441
|
5.444
|
22.3
|
7.218
|
7.076
|
8.156
|
27.13
|
11.69
|
12.58
|
EBIT
1 |
4.141
|
-7.273
|
-9.082
|
-6.788
|
6.085
|
-8.177
|
-5.961
|
-5.057
|
12.73
|
-5.464
|
-5.108
|
-2.857
|
16.87
|
-0.5318
|
-0.0095
|
Operating Margin
|
8.7%
|
-20.16%
|
-24.52%
|
-17.61%
|
11.55%
|
-19.94%
|
-12.98%
|
-11.09%
|
19.59%
|
-10.66%
|
-9.71%
|
-5.1%
|
21%
|
-0.84%
|
-0.01%
|
Earnings before Tax (EBT)
1 |
4.209
|
-7.091
|
-8.963
|
-6.556
|
6.622
|
-7.495
|
-5.02
|
-3.946
|
14.09
|
-3.862
|
-4.325
|
-2.074
|
17.66
|
0.0532
|
0.6002
|
Net income
1 |
4.535
|
-7.091
|
-8.963
|
-6.577
|
5.922
|
-7.495
|
-5.02
|
-3.66
|
12.99
|
-3.862
|
-4.271
|
-1.865
|
15.5
|
0.217
|
1.081
|
Net margin
|
9.53%
|
-19.66%
|
-24.19%
|
-17.06%
|
11.24%
|
-18.27%
|
-10.93%
|
-8.03%
|
19.99%
|
-7.53%
|
-8.12%
|
-3.33%
|
19.29%
|
0.34%
|
1.62%
|
EPS
2 |
0.0900
|
-0.1500
|
-0.1900
|
-0.1400
|
0.1300
|
-0.1600
|
-0.1100
|
-0.0800
|
0.2600
|
-0.0800
|
-0.0900
|
-0.0386
|
0.2943
|
0.0100
|
0.0233
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/4/22
|
8/3/22
|
11/9/22
|
2/23/23
|
5/10/23
|
8/2/23
|
11/8/23
|
2/29/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-9.8
|
14.9
|
-
|
10.1
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
2.33%
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
1.6%
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
179.4
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
2.63
|
-
|
7.6
|
20
|
19.5
|
11.8
|
14.9
|
Capex / Sales
|
-
|
2.11%
|
-
|
4.62%
|
10.13%
|
8.09%
|
3.92%
|
3.93%
|
Announcement Date
|
2/25/20
|
2/24/21
|
2/24/22
|
2/23/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
45.07
USD Average target price
55.33
USD Spread / Average Target +22.77% Consensus |
1st Jan change
|
Capi.
|
---|
| +26.57% | 2.19B | | +6.58% | 41.61B | | -11.57% | 33.32B | | +79.15% | 28.8B | | -14.73% | 15.61B | | -6.00% | 13.27B | | -12.55% | 11.46B | | +166.50% | 10.06B | | -54.80% | 9.09B | | +4.19% | 8.9B |
Biopharmaceuticals
|